

## AUGMENTATION OF K<sup>+</sup> CHANNEL EXPRESSION USING ADENOVIRAL VECTORS

### FIELD OF THE INVENTION

[0001] The present invention relates to the augmentation of K<sup>+</sup> channel expression using adenoviral vectors and more particularly to gene therapy for pulmonary hypertension, patent ductus arteriosus and other vascular diseases.

### BACKGROUND OF THE INVENTION

[0002] Exposure to chronic hypoxia reliably leads to the development of chronic hypoxic pulmonary hypertension (CH-PHT). CH-PHT is a model for the PHT that occurs in patients with chronic lung diseases or people residing at high altitude. Hypoxic pulmonary vasoconstriction (HPV) is selectively blunted in rats with CH-PHT, whilst response to other vasoconstrictors is preserved or enhanced, as discussed in McMurtry IF, et al. (1978) *Am J Physiol.* 235:H104-H109; and Isaacson TC, et al. (1994) *J. Appl. Physiol.* 76:933-940.

[0003] The loss of O<sub>2</sub> sensitivity and development of PHT are associated with decreased expression of O<sub>2</sub> and 4-aminopyridine (4-AP)-sensitive K<sup>+</sup> channels (Kv1.5 and Kv2.1), both in cultured pulmonary artery smooth muscle cells (PASMC), as discussed in Wang J, et al. (1997) *J. Clin. Invest.* 100:2347-2353, and intact Pas, as discussed in Reeve HL, et al. (2001) *J Appl Physiol.* 90:2249-56.

[0004] HPV is a vasomotor response that occurs in the pulmonary circulation in response to alveolar hypoxia. HPV occurs in small resistance pulmonary arteries (PA) and serves to constrict arteries supplying hypoxic alveoli. This improves ventilation to perfusion matching in the lung and thereby optimizes systemic oxygenation. HPV is intrinsic to the PA, occurring ex vivo in isolated, perfused lungs and PA rings. In addition, HPV has also been demonstrated in isolated PASMCs, suggesting that the fundamental mechanism, though modulated importantly by many endothelial mediators, is intrinsic to the PASMC. In the pulmonary circulation, Kv channels, including  $\alpha$ -

subunits of Kv1.5 and Kv2.1, are responsible for determining the membrane potential of PASMCs. Inhibition of PASMC Kv channels with 4-AP results in pulmonary vasoconstriction. As  $K^+$  current ( $I_K$ ) is inhibited, the plasmalemmal membrane potential ( $E_M$ ) depolarizes, thereby increasing the opening of L-type voltage-dependent  $Ca^{++}$  channels, increasing inward  $Ca^{++}$  current and activating the contractile apparatus, causing vasoconstriction. Likewise, hypoxia inhibits  $I_K$  and depolarizes rat PASMCs. Candidate  $O_2$ -sensitive Kv channels that have been implicated in this response are Kv1.5 and Kv2.1/9.3, as discussed in Patel AJ, et al., (1997) *Embo J.* 16:6615-25 and Archer SL, et al. (1998) *J Clin Invest.* 101:2319-30, in addition to Kv1.2 and Kv3.1b, as discussed in Hulme JT, et al. (1999) *Circ Res.* 85:489-97, and Osipenko ON, et al., (2000) *Circ Res.* 86:534-40.

[0005] Pharmacologic evidence has recently been provided to show that  $O_2$ -induced constriction of the human ductus arteriosus (DA) also involves inhibition of voltage-gated potassium channels (Kv) in ductus arteriosus smooth muscle cell (DASMC), as discussed in Michelakis E, et al. (2000) *Lancet* 356:134-7.

[0006] In the fetus, the ductus arteriosus (DA) is tonically relaxed by its hypoxic environment. This allows venous blood to bypass the nonventilated lungs. At birth, simultaneous pulmonary vasodilatation and DA vasoconstriction direct right ventricular blood flow into the pulmonary circulation. Functional closure of the DA (due to vasoconstriction) precedes anatomical closure (due to cell proliferation) by days and is crucial to the newborn's transition to an air-breathing organism. The DA constrictor response to  $O_2$ , though modulated by the endothelium (reinforced by endothelin, ET, and inhibited by vasodilatory prostanoids and nitric oxide, NO), is intrinsic to the DA smooth muscle cell (DASMC).  $O_2$  constriction persists ex vivo, following endothelial-denudation, and despite inhibition of prostaglandin H synthase (PGHS), nitric oxide synthase (NOS) and ET-A receptors. As in most arteries, this  $K^+$  channel inhibition leads to SMC depolarization, opening of the voltage-gated L-type  $Ca^{++}$  channels, influx of  $Ca^{++}$  and vasoconstriction. However, the molecular identity of the relevant DASMC Kv channels, as well as the mechanism of  $O_2$  sensing in this important human vessel, remain unknown.

[0007] Vascular  $O_2$  sensing systems consist of a sensor, the function of which is altered by changes in  $PO_2$ , a mediator, produced by this sensor, and an effector, which alters vascular tone in

response to the mediator. Many aspects of the O<sub>2</sub> sensor-effector pathway are conserved amongst O<sub>2</sub>-sensitive mammalian tissues, the pulmonary artery (PA), the DA, the adrenomedullary cells, the neuroepithelial body and the carotid body. In each tissue, K<sup>+</sup> channels have been implicated in the effector mechanism, as discussed in Archer SL, et al., (2000) *Adv Exp Med Biol.* 475:219-40, whilst the O<sub>2</sub> sensor has been proposed to involve a change in redox state, as determined by mitochondria or NADPH oxidase.

[0008] Attention has focused on the mitochondria because electron transport chain (ETC) inhibitors mimic hypoxia, constricting the PA and activating the carotid body. Mitochondria respond to changes in PO<sub>2</sub> by altering their respiration and production of reactive O<sub>2</sub> species (ROS). This changes cellular redox potential and alters the function of many redox-sensitive genes, second messenger systems and O<sub>2</sub>-sensitive K<sup>+</sup> channels in the membrane, prior to any depletion of ATP. Because K<sup>+</sup> channels control SMC membrane potential (E<sub>m</sub>), and thus tone, in most vascular beds, O<sub>2</sub> sensitive K<sup>+</sup> channels are attractive candidate effectors in vascular redox-based O<sub>2</sub> sensing systems. O<sub>2</sub>-sensitive K<sup>+</sup> channels include homo- and heterotetramers composed of the several Kv  $\alpha$ -subunits (Kv1.2, Kv1.5, Kv2.1, Kv3.1b, Kv4.3, Kv9.3) and the calcium-sensitive K<sup>+</sup> channels, BK<sub>Ca</sub>, as discussed in Hulme Jt et al., (1999) *Circ Res.*;85:489-97; Archer SL, et al., (1998) *J Clin Invest.* 101:2319-30; Patel AJ, et al., (1997) *EMBO J.* 16:6615-25; Perez-Garcia MT, et al., (2000) *J Neurosci.* 20:5689-95; Cornfield DN, et al., (1996) *Proc. Natl. Acad. Sci.* 93:8089-8094; and Riesco-Fagundo AM, et al., (2001) *Circ Res.* 89:430-6. In rabbit DAs, O<sub>2</sub>, and oxidants such as H<sub>2</sub>O<sub>2</sub>, inhibit DASMCM Kv current and depolarize E<sub>m</sub>, leading to vasoconstriction.

[0009] Previous studies suggest that decreased expression and activity of Kv channels is causally related to the loss of HPV and the development of CH-PHT. Previous studies also suggest that O<sub>2</sub> constricts the human DA via inhibition of DASMCM Kv channels. The present invention relates to the restoration of Kv channels, using selective gene transfer accomplished by nebulization of an adenoviral vector, for reducing CH-PHT and restoring HPV.

[0010] All publications cited herein are hereby incorporated by reference in their entirety.

## SUMMARY OF THE INVENTION

[0011] In a broad aspect the present invention provides an expression vector, preferably a recombinant adenoviral vector, comprising nucleic acid encoding at least one K<sup>+</sup> channel gene, operably linked to a promoter. In an alternative embodiment of the invention the vector further comprises a reporter gene operably linked to the nucleic acid.

[0012] The present invention further provides a method of treating a vascular disease comprising administering to a person having a vascular disease a composition comprising an expression vector, preferably a recombinant adenoviral vector, encoding at least one K<sup>+</sup> channel gene operably linked to a promoter, and a pharmaceutically acceptable excipient. In an alternative embodiment of the invention the vector further comprises a reporter gene operably linked to the nucleic acid. This vector may be administered by, for example, nebulization of the airway, by intravascular routes or by direct injection (or topically).

## BRIEF DESCRIPTION OF THE DRAWINGS

[0013] The invention will be better understood with reference to the attached detailed description and to the following Figures, wherein:

[0014] Figure 1 illustrates the effect of gene transfer on pulmonary vascular resistance index (PVRI), cardiac index (CI), pulmonary artery pressure (PAP) and right ventricular/left ventricular plus septum measurements;

[0015] Figure 2A illustrates representative traces to show that the normal magnitude of HPV is blunted in the CH-PHT;

[0016] Figure 2B shows the effect of gene transfer on HPV and AII;

[0017] Figure 3A illustrates a representative confocal microscopy images showing green fluorescence in a lung section from a CH-Ad5-Kv1.5 rat and a CH-S rat;

[0018] Figures 3B and C are immunoblots on lung tissue for GFP, Kv1.5, and Kv2.1;

- [0019] Figure 4 is an immunohistochemistry for human Kv1.5 and illustrates Kv1.5 overexpressed in CH-Ad5-Kv1.5 Pas;
- [0020] Figures 5 and 6 illustrate the effect of gene transfer on  $K^+$  Current density;
- [0021] Figures 7A-E illustrate Kv channels control of DA tone;
- [0022] Figure 8 illustrates mRNA $\leq$  Kv1.5 and Kv2.1 expressed in the media and SMCs of DA;
- [0023] Figure 9A-F illustrates the parallel effects of ETC-inhibitors and hypoxia on tone and  $I_K$  in human DA;
- [0024] Figure 10A and B illustrate the exposure of DA to chronic normoxia causes loss of sensitivity of tone and  $I_K$  to both  $O_2$  and 4-AP;
- [0025] Figure 11A shows the confocal microscopy of DA rings;
- [0026] Figure 11B shows the confocal microscopy for DASMCS grown in normoxic versus hypoxic primary culture;
- [0027] Figures 11C and D illustrate  $E_M$  measured in green fluorescent units in chronically normoxic DASMCS and chronic hypoxic controls;
- [0028] Figure 11E illustrates the results of qRT-PCR for Kv1.5 and Kv2.1 mRNA in tissue cultured rings;
- [0029] Figure 12A shows ex vivo gene transfer in intact DA rings confirmed by confocal microscopy;
- [0030] Figure 12B illustrates the Kv current in DASMCS from the infected DA;
- [0031] Figure 12C illustrates the results of qRT-PCR specific for the expression of rat Kv2.1 in Das;

[0032] Figures 12D and E illustrates that Kv2.1 gene transfer significantly restores the responsiveness of the chronically normoxic DA ring to both 4-AP and O<sub>2</sub>;

[0033] Figure 13A and B are images of human DASMCM showing an elaborate mitochondrial network (100X);

[0034] Figure 13C illustrates the effects of antimycin, rotenone and cyanide on TMRM-loaded DASMCM mitochondria;

[0035] Figures 14A and B illustrate the effects on Lucigenin-enhanced chemiluminescence and H<sub>2</sub>O<sub>2</sub> production when PO<sub>2</sub> levels are increased in isolated human DA rings;

[0036] Figures 14C and D illustrate the effects of t-butyl-H<sub>2</sub>O<sub>2</sub> on DASMCMs;

[0037] Figure 14E illustrates the proposed mechanism for O<sub>2</sub>-constriction in the DA;

[0038] Figure 15 illustrates the calibration curve for the AmplexRed assay;

[0039] Figure 16 is an immunohistochemistry showing the presence of Kv2.1 and Kv1.5  $\alpha$ -subunit proteins in DASMCMs;

[0040] Figure 17 illustrates the RT-PCR was performed on individual ducti;

[0041] Figure 18 illustrates the expression of subunits of ETC complexes I-IV in DA rings; and

[0042] Figure 19 is shows the TMRM images of the mitochondria of a HL-1 cardiac myocyte cell line and DASMCMs.

#### DETAILED DESCRIPTION OF THE INVENTION

[0043] The present invention discloses the administration of Kv channel genes, and more preferably Kv1.5, to the pulmonary circulation via an aerosol, and effectiveness of the administration in eliciting transgene expression in resistance PASMCMs. The administration of Kv1.5, cloned from human PA, reduces PVRI in experimental PHT. Kv gene therapy with an O<sub>2</sub>-sensitive channel

restores HPV and O<sub>2</sub> sensitive I<sub>K</sub> in rats with established CH-PHT. Examples of the K<sub>v</sub> channel genes that may be administered include, but are not limited to, Kv1.5, Kv2.1/9.3, large conductance calcium-sensitive K<sup>+</sup> channel, Kv1.2, Kv3.1 and BK<sub>Ca</sub>.

[0044] The present invention further discloses the administration of K<sub>v</sub> intravascularly, and more preferably Kv2.1, preferably by catheter, for modulation of tone in the patent ductus arteriosus.

[0045] The present invention further discloses an expression vector comprising nucleic acid encoding at least one K<sup>+</sup> channel gene operably linked to a promoter. The present invention further discloses the vector having a reporter gene operably linked to the nucleic acid. The vector can be used in the administration of K<sub>v</sub> to the pulmonary circulation. Preferably the expression vector is an adenoviral vector, and more preferably the expression vector is a replication-deficient adenoviral vector. However, it will be understood by a person skilled in the art that any vector system may be used in the treatment of vascular disease that has a suitable efficiency for gene transfer and for long term expression, examples include, but are not limited to, the gutless adenovirus, lenti virus, naked DNA, nonviral vectors, adenoassociated virus, cationic polymers of the polylysine, polyethlenimine, an DEAE-neutral lipids, lipofectants, cationic lipids such as lipopolyamines and the herpes virus.

[0046] Preferably the promoter that is used is a tissue specific promoter. Examples of promoters that may be used include, but are not limited to, the CMV promoter and the SM-22 promoter. It will be understood by a person skilled in the art that any suitable reporter gene may be used. Examples include, but are not limited to, the green fluorescent protein gene (GFP) and the myc tag.

[0047] The present invention further provides an isolated host cell stably transformed with an expression vector comprising nucleic acid encoding at least one K<sup>+</sup> channel gene operably linked to a promoter.

[0048] The present invention further provides an article of manufacture comprising packaging material within which is contained a nebulizable formulation useful to treat a vascular disease, wherein the formulation comprises an expression vector comprising nucleic acid encoding at least one K<sup>+</sup> channel gene operably linked to a promoter with a pharmaceutically excipient, and the

packaging material comprises a label which indicates that the formulation can be used to treat a vascular disease.

[0049] The present invention is directed to the central role for Kv1.5 in the mechanism of HPV. Not only do mice lacking Kv1.5 have suppressed HPV, but in a different model, CH-PHT, loss of Kv1.5 is associated with blunted HPV which can be restored by Kv1.5 gene transfer. This invention also supports the hypothesis that a K<sup>+</sup> channel deficiency state may be involved in the pathogenesis of PHT as described in Yuan X-J, et al., (1996) *Circulation* 94:1-49, and Archer S, and Rich S, (2000) *Circulation* 102:2781-91.

[0050] Acute exposure to segmental alveolar hypoxia results in vasoconstriction of small arteries supplying hypoxic alveoli. In the setting of acute, focal airway hypoxia, HPV is an adaptive response that shunts blood from hypoxic alveoli to non-hypoxic alveoli hence optimizing systemic oxygenation. However, it is known that if exposure to alveolar hypoxia continues, particularly if the hypoxia is global, HPV is suppressed. The present invention shows that in rats with confirmed PHT the response to acute hypoxia, but not AII, was depressed, as shown in Figure 2, consistent with previous reports described in McMurtry IF, et al. (1980) *Am J Physiol.* 238:H849-57 and Reeve HL, et al., (2001) *J Appl Physiol.* 90:2249-56. Teleologically, this decrease in HPV may be advantageous in that it minimizes right ventricular strain resulting from global pulmonary vasoconstriction under circumstances in which HPV cannot augment O<sub>2</sub> uptake. Thus, although CH-PHT may be initiated by HPV, this response is downregulated and the PHT appears to be sustained by the remodeling of the pulmonary vasculature, characterized by distal extension of smooth muscle to previously nonmuscular arteries and medial hypertrophy.

[0051] The loss of Kv1.5 expression appears to be important to the pathogenesis of various forms of PHT, including CH-PHT, as described in Reeve HL, et al., (2001) *J Appl Physiol.* 90:2249-56; Michelakis ED, et al., (2002) *Circulation*;105:244-50; and Yuan X-J, et al., (1996) *Circulation* 94:1-49. This concept is now supported by the finding that augmentation of Kv1.5 channel expression by gene transfer reduces PHT, as shown in Figure 1. The reduction in PVRI was largely the result of increased cardiac index, rather than a fall in mean PAP, as shown in Figure 1. This type of response is not uncommonly seen in patients with PHT, as described in Rich S, et al. (1985) *Am J*



Cardiol. 55:159-163. Because both the aortic pressure, measured by a high-fidelity catheter, and SVRI were not different between in CH-S versus CH-Ad5-Kv1.5 groups, this suggests that the increased CI is due to decreased RV afterload (pulmonary vasodilatation). The possibility of systemic leak of nebulized Kv1.5 transgene cannot completely be excluded, which theoretically could increase CI by enhancing cardiac inotropy or promoting peripheral vasodilatation. A decrease in RV afterload did not reverse right ventricular hypertrophy. It is likely that regression of RVH requires a longer therapeutic interval than the 3 days allowed post gene transfer in this protocol.

[0052] What is the molecular mechanism of the loss of HPV in CH-PHT? There is substantial evidence that Kv channel inhibition initiates HPV. In particular, selective inhibition of Kv1.5, an O<sub>2</sub> and 4-AP-sensitive Kv channel, whether by administration of an antiKv1.5 antibody, as described in Archer SL, et al. (1998) J Clin Invest. 101:2319-30, or by Kv1.5 gene deletion, as discussed in Archer SL, et al., (2001) FASEB J. 15:1801-1803, reduces O<sub>2</sub> sensitive Kv current in isolated PSMCs and also significantly impairs HPV. Kv1.5 is important to HPV and its loss reduces HPV. Kv1.5 expression in PAs is also selectively downregulated in both human pulmonary arterial hypertension, as described in Yuan XJ, et al., (1998) Lancet 351:726-7 and experimental models of pulmonary hypertension, as described in Reeve HL, et al., (2001) J Appl Physiol. 90:2249-56 and Yuan X-J, et al., (1993) Am. J. Physiol. 264:L116-L123. Kv1.5 is inhibited by anorexigens, such as dexfenfluramine, which have caused outbreaks of human PHT.

[0053] In CH, PSMCs are depolarized, and their  $I_K$  is less sensitive to 4-AP and hypoxia as shown in Figure 6. These physiological and electrophysiological abnormalities are associated with, and presumably result from, down regulation of Kv1.5, and Kv2.1.

[0054] Kv1.5 expression is dynamically regulated, both at the level of transcription as well as post-translationally. Kv1.5 mRNA has a very short half-life and Kv1.5 protein turnover is also rapid. In addition, the Kv1.5 gene has cyclic adenosine monophosphate and glucocorticoid response elements. The rapid response is consistent with the rapid loss of HPV, that occurs within 1-2 days of CH. CH could decrease Kv1.5 expression by decreasing Kv1.5 gene transcription, destabilizing Kv1.5 mRNA or accelerating turnover of Kv1.5 protein. The fact that CH suppresses genomic, but not episomal Kv1.5 expression, suggests that the control of endogenous Kv1.5 gene is regulated at a

transcriptional level, since the human Kv1.5 mRNA and protein are not suppressed by the ongoing hypoxia. It is thought that CH may activate KRE (Kv1.5 repressor element), a dinucleotide repetitive DNA sequence forming a cell-specific silencer, as described in Mori Y, et al., (1995) J Biol Chem. 270:27788-96. When activated, this K<sup>+</sup> channel repressor element inhibits transcription of the Kv1.5 gene. The episomal location and promiscuous promoter driving expression of human Kv1.5 in this rat model were not susceptible to downregulation of CH.

[0055] As discussed above the present invention also relates to a vector that permits the delivery of an important human Kv channel to the pulmonary circulation. As shown in the examples the use of Kv1.5 cloned from the PA of a normal human allows the detection of only the specific expression of the human gene by qRT-PCR, without interference from endogenous rat Kv1.5. The inclusion of GFP in the vector allows detection of transgene expression using fluorescent microscopy without tissue destruction.

[0056] As discussed above, the present invention provides for Kv gene transfer, for example Kv1.5 gene transfer, via airway nebulization in vivo to increase transgene expression in resistant PAs and reverse increased PVRI.

[0057] The present invention further illustrates the mechanism of O<sub>2</sub> sensing in the human DA. As can be seen in Figures 7 and 8, Kv channels are the effectors of O<sub>2</sub>-constriction. Inhibiting these channels, whether by 4-AP or O<sub>2</sub> leads to vasoconstriction. The proximal mitochondrial ETC serves as the O<sub>2</sub> sensor, as shown in Figures 9, 10A, and 13. Inhibition of the complex I or III inhibits O<sub>2</sub> constriction. Consistent with data in rabbit DA, the mediator linking the sensor and effector in the human DA appears to be a ROS (H<sub>2</sub>O<sub>2</sub>) (Figure 14). The ability of hypoxia and proximal ETC inhibitors to depolarize  $\Psi_m$  (Figure 13) provides a probable mechanism by which hypoxia alters ROS production. In addition, a new model of ionic remodeling is disclosed which is useful in understanding the relative contributions of Kv channels and mitochondria to O<sub>2</sub>-sensing in the human DA (Figure 10-12). Together, these findings suggest that ROS produced in the proximal ETC in response to O<sub>2</sub> could be redox mediators that link the mitochondrial sensor to the Kv effector and thus control tone, as illustrated schematically in Figure 14D.

[0058] Roulet and Coburn first demonstrated that O<sub>2</sub>-induced DA constriction is associated with membrane depolarization, as described in Roulet M.J., and Coburn R.F. (1981) *Circ. Res.* 49:997-1002. Although the K<sup>+</sup> channel effector mechanism is widely conserved amongst O<sub>2</sub> sensitive tissues, the type of K<sup>+</sup> channel and downstream response to channel inhibition may vary amongst species, between tissues and with maturation. The present invention discloses the mechanism of O<sub>2</sub> constriction in term human DA, maintained in their normal hypoxic environment, except when they were intentionally exposed to acute or chronic normoxia. Despite the congenital heart disease, these DAs have normal responses to O<sub>2</sub> with similar thresholds for onset of O<sub>2</sub> constriction and maximal O<sub>2</sub> responses, as described in Tristani-Firouzi M, et al., (1996) *J. Clin. Investigation* 98:1959-1965, and Michelakis E, et al., (2000) *Lancet* 356:134-7.

[0059] In the human DA, O<sub>2</sub> and 4-AP cause nonadditive vasoconstriction. Nifedipine, an inhibitor of L-type Ca<sup>++</sup> channels, blocks both 4-AP and O<sub>2</sub> constriction consistent with an obligatory and coordinated role for Kv and Ca<sup>++</sup> channels in O<sub>2</sub> constriction. The present invention confirms the ability of Kv, but not BK<sub>Ca</sub>, channel blockers to constrict the human DA and demonstrates a strong correlation between the magnitude of 4-AP constriction and O<sub>2</sub> constriction (Figure 7A-B). The basis for these physiological observations is disclosed. The DAsMCs express several O<sub>2</sub> and 4-AP sensitive K<sup>+</sup> channels, which are involved in hypoxic pulmonary vasoconstriction (Kv1.5 and Kv2.1) and O<sub>2</sub> responses in the carotid body, as shown in Figures 2 and 17.

[0060] A new model was developed to further understand the role of Kv channels in O<sub>2</sub> constriction. In this model, designed to mimic the conditions in the first days post birth, exposure to tissue culture conditions ex vivo (particularly at normoxic PO<sub>2</sub>), inhibited DAsMC I<sub>K</sub>, as shown in Figure 4B and downregulated several O<sub>2</sub>-sensitive Kv channels, including Kv1.5 and Kv2.1, as shown in Figure 5E. The results shown in Figures 15-19 show that expression of other O<sub>2</sub>-sensitive channels, Kv4.3, Kv9.3 and BK<sub>Ca</sub> channels also decrease in this model. However, the lack of effect of iberiotoxin on tension suggests that the role for BK<sub>Ca</sub> channels may be less important in O<sub>2</sub> response in the DA than in the carotid body. The role of Kv4.3 is somewhat less likely as these

channels generate a rapidly inactivating current, unlike the slow-noninactivating O<sub>2</sub> sensitive current in DASMCs.

[0061] The loss of these Kv channels is associated with membrane depolarization, as shown in Figure 11A-C, and impaired ability of the membrane to further depolarize to either O<sub>2</sub> or 4-AP, as shown in Figure 5D, even hours after the DASMC are returned to a hypoxic environment. These changes in the electrical properties of the DA are termed *ionic remodeling*. Similar ionic remodeling and loss of O<sub>2</sub> responsiveness has also been reported in other O<sub>2</sub>-sensitive tissues. Loss of acute hypoxic pulmonary vasoconstriction, which occurs with chronic hypoxia, is also associated with downregulation of Kv2.1 and Kv1.5 expression and loss of the O<sub>2</sub>-sensitive portion of I<sub>K</sub>, as described in Reeve HL, et al., (2001) J Appl Physiol. 90:2249-56, and Michelakis ED, et al., (2002) Circulation 105:244-50.

[0062] The ionic remodeling model further highlights the importance of the Kv channels to O<sub>2</sub>-induced constriction. The reduction in K<sup>+</sup> current density is associated with loss of sensitivity of current and tone to O<sub>2</sub> and 4-AP (Figure 10). Furthermore, rotenone's ability to increase I<sub>K</sub> is lost in this model (Figure 10B). Coupled with the qRT-PCR evidence for loss of O<sub>2</sub>-sensitive channels, but not ETC complexes, as shown in Figure 18, these data suggest that the loss of O<sub>2</sub> constriction is primarily due to modifications of the Kv effector, rather than the mitochondrial sensor. Consistent with this interpretation, restoration of Kv2.1 expression by ex vivo gene transfer significantly restores the constriction to both 4-AP and O<sub>2</sub> (Figure 12). The fact that restoration of O<sub>2</sub> and 4-AP constriction is incomplete after Kv2.1 restoration may relate to the fact that other downregulated O<sub>2</sub> and 4-AP sensitive channels (e.g. Kv1.5, Kv9.3, Kv4.3) were not replaced. Alternatively, alterations in function of other components of the contractile apparatus may be abnormal.

[0063] Although the pulmonary artery and the DA are contiguous, their response to O<sub>2</sub> is reversed. Hypoxia causes pulmonary vasoconstriction versus DA relaxation. Similar Kv channels are present in both arteries. The fact that the Kv inhibitor 4-AP constricts both arteries suggests that the Kv channels setting E<sub>M</sub> in the two tissues may be similar. By extension, this implies that their differential O<sub>2</sub> response may relate to differences in either the O<sub>2</sub>-sensor or the response of the K<sup>+</sup> channels to the redox messenger produced by a shared sensor. In human DA, it appears that O<sub>2</sub>-

sensitive Kv channels are the effectors and the mitochondrial ETC is the O<sub>2</sub> sensor, very similar to the pulmonary artery. What differs is the response to ROS.

[0064] The evidence that Kv function and vascular tone are regulated by mitochondria comprises first, rotenone and antimycin mimic hypoxia better than any other class of drugs, suggesting a role for mitochondria in vascular O<sub>2</sub> sensing. Proximal ETC inhibition causes pulmonary vasoconstriction, systemic dilatation, carotid body activation, and DA vasodilatation, as shown in Figure 9. Rotenone and antimycin, but not cyanide, selectively inhibit O<sub>2</sub> constriction in the human DA and reverse O<sub>2</sub>-induced inhibition of I<sub>K</sub> in DASMCs, as shown in Figure 9D-F. The effects of rotenone and antimycin are additive and the combination completely prevents O<sub>2</sub> constriction, without preventing phenylephrine constriction, as shown in Figure 9A. In addition, the more a DA constricts to O<sub>2</sub> the more relaxation occurs in response to rotenone, but not to cyanide, as shown in Figure 8C. These findings are a mirror image of those in the pulmonary circulation where ETC inhibitors, also mimicking hypoxia, cause pulmonary vasoconstriction and inhibition of I<sub>K</sub>. However, in both the pulmonary circulation and DA, hypoxia and ETC inhibitors decrease ROS production, as shown in Figure 14, suggesting the difference between the vessels relates to their K<sup>+</sup> channels' response to H<sub>2</sub>O<sub>2</sub> and ROS. Indeed, DASMCs depolarize in response to H<sub>2</sub>O<sub>2</sub>, as shown in Figure 14, the opposite of the response seen in pulmonary artery SMCs.

[0065] The link between the mitochondria, Kv channels and tone is through a redox mediator, rather than ATP levels, as shown in Figure 14D. Although mitochondria have been dismissed as poor candidates for O<sub>2</sub> sensing because the K<sub>m</sub> of their cytochromes may be too low for modulation by physiologic levels of hypoxia, they exhibit a reversible inhibition of respiration during prolonged hypoxia due to inhibition of cytochrome c oxidase. Mitochondria are increasingly recognized to be involved in intracellular Ca<sup>++</sup> control and in redox signaling, in part, because they are important sources of ROS.  $\Psi_m$ , a major determinant of cellular redox potential, changes rapidly over a physiological range of PO<sub>2</sub> values in type I carotid body cells, depolarizing in response to hypoxia and metabolic inhibitors. Similarly, hypoxia, rotenone and antimycin depolarize  $\Psi_m$  in human DASMCs within 1-2 minutes, as shown in Figure 13 and this is associated with impaired ROS production, as shown in Figure 14 A-B. The confocal images also show that the mitochondria in

DASMC, far from being remote from the plasma membrane, form a ubiquitous, filamentous network that permeates the cytosol and is thus positioned to signal changes in  $PO_2$  to all cellular compartments, including the plasma membrane, as shown in Figure 13.

[0066] The examples suggest that the increase in the  $H_2O_2$  levels that occurs with normoxia at the time of birth inhibits DASMC Kv current, causing depolarization and vasoconstriction. Indeed, in human DAs,  $H_2O_2$  production increases as  $PO_2$  rises, as shown in Figure 14A-B and  $H_2O_2$  inhibits  $I_K$  and causing membrane depolarization, as shown in Figure 8C-D. Likewise, in rabbit DASMC, intracellular administration of physiological doses of  $H_2O_2$  decreases  $I_K$  and these effects are inhibited by catalase. The molecular basis for the differential electrophysiological response to  $H_2O_2$  in the pulmonary artery SMC (activation) versus the DASMC (inhibition) is unknown. Possible explanations include tissue-specific differences in  $K^+$  channel heterotetramer composition,  $\alpha$ -subunit splice variants, sulfhydryl redox state of key channel amino acids, or  $\beta$ -subunit expression.

[0067] The present invention will now be illustrated by reference to the following examples which set forth particularly advantageous embodiments. However, it should be noted that these embodiments are illustrative and are not to be construed as restricting the invention in any way.

## EXAMPLES

### Methods and Materials

[0068] The following methods and materials relate to Examples 1-6.

### Adenovirus Vector

[0069] A recombinant, replication-deficient adenovirus encoding GFP and Kv1.5 was prepared as previously described in Michelakis ED, et al. (2002) Circulation 105:244-50 and Michelakis ED, et al. (2001) Adv Exp Med Biol. 502:401-18.

[0070] A 2.1 kb cDNA fragment of Kv1.5 was obtained by reverse transcription of mRNA derived from the proximal pulmonary artery of a cardiac transplant donor. The cDNA was inserted downstream of a CMV promoter in the pAdTrack-CMV shuttle vector. The resultant pAdTrack-

CMV Kv1.5 construct was linearized with a PmeI restriction endonuclease digest, transformed together with an adenoviral plasmid (Adeasy-1) into bacterial BJ5183 cells and plated on LB plates containing kanamycin. Subsequent colonies were isolated and cultured, and the resulting plasmid DNA was purified. The plasmid containing Kv1.5 cDNA within the adenoviral DNA was selected, amplified, purified, linearized (Pac I restriction endonuclease), and transfected into HEK 293 cells with LipofectAmine reagent. Plates that demonstrated complete cell lysis were collected and analyzed for the expression of human Kv1.5 using polymerase chain reaction. Multiple rounds of Ad5-Kv1.5 replication were performed in HEK 293 cells. The resulting virus was isolated, precipitated, and concentrated by step-wise discontinuous CsCl gradient. The final viral titer was  $1.5 \times 10^9$  pfu/mL.

#### Exposure to Hypoxia

[0071] Rats developed CH-PHT by being placed in a normobaric hypoxic chamber (Reming Bioinstruments, Redfield, NY). They were gradually acclimatized to a final 10% O<sub>2</sub> environment over a 2week time period of increasing hypoxia, as previously described in Michelakis ED, et al. (2002) *Circulation* 105:244-50.

#### In Vivo Gene Delivery to the Lung

[0072] All rats were housed, 2-3 per cage, and exposed to a 12:12 hour light cycle, and fed standard rat chow and water ad libitum. Adult male, Sprague-Dawley rats were randomized into the following groups: Normoxic-saline (N-S), CH saline (CH-S), CH-adenovirus (5) + green fluorescent protein reporter (CH-Ad5-GFP), and CH + Ad-5 + GFP + Kv1.5 gene (CH-Ad5-Kv1.5). The dose of virus was based on preliminary experiments, showing that this dose caused demonstrable Kv1.5 transgene expression without undue toxicity. Each rat was anesthetized with ketamine (60 mg/kg IP) and rompun (10mg/kg IP, both drugs from Health Sciences Laboratory Animal Services, Edmonton, Alberta) and oro-tracheally intubated with PE-240 tubing (Intramedic, VWR Canlab, Mississauga, ON) during tracheal trans-illumination. The rats breathed spontaneously while intubated. Solution, containing either sterile saline, Ad5-GFP, or Ad5-GFP-Kv1.5 in 100μL was nebulized via an intratracheal microspray device (Penn-Century Inc. MicroSprayer, Philadelphia, PA) placed in the

endotracheal tube lumen. The animals were then allowed to recover from anesthesia spontaneously. The CH rats were returned to the hypoxic chamber after recovery (24 – 48 hours). Experimentation began 72 hours after treatment to allow infection and transgene expression to occur. Sample sizes (n/group) were: hemodynamics (6), isolated lung perfusion (7), immunoblotting, RT-PCR, immunohistochemistry, and confocal imaging (3), and patch clamping (10).

### Hemodynamic Measurements

[0073] Pulmonary artery pressure (PAP) was measured in closed chest rats with a 1.4F, micromanometer-tipped catheter (Millar Instruments, Houston Texas), as previously described in Michelakis ED, et al. (1999) *J Pharmacol Exp Ther.* 291:1143-9. The mean PAP was determined by electronic averaging over one minute. Left ventricular end-diastolic pressure (LVEDP) was measured via retrograde cannulation of the left ventricle and systemic blood pressure (SBP) via the right common carotid artery. Cardiac output was measured using the Fick method, as discussed in Michelakis ED, et al. *Circulation.* 2002;105:244-50. Cardiac index (CI) was calculated as CO/weight (kg). Pulmonary vascular resistance index (PVRI) was calculated as PAP-LVEDP/CI. As a measure of right ventricular hypertrophy (RVH), the ratio of RV/LV + septum (g) was measured as previously described in Archer SL, et al. (1989) *J Appl Physiol.* 66:1662-73. Systemic Vascular Resistance Index (SVRI) was measured as MAP-right atrial pressure/CI.

### Isolated Lung Perfusion

[0074] The isolated perfused lung model was performed as previously described in Archer S, et al. (1987) *Cardiovasc Res.* 21:928-32. Flow of perfusate (Krebs solution containing 4% bovine serum albumin) was maintained constant at 0.04 mL/g/min by a continuous roller pump. Therefore, changes in PAP solely reflected changes in pulmonary vascular resistance. Throughout the protocol the lungs were ventilated with either hypoxic humidified gas (2.5 % O<sub>2</sub>, 5 % CO<sub>2</sub>, balance N<sub>2</sub>) or normoxic humidified gas (20 % O<sub>2</sub>, 5 % CO<sub>2</sub>, balance N<sub>2</sub>). The experimental protocol was performed in the presence of the nitric oxide synthase inhibitor N<sup>G</sup>-nitro-L-arginine methyl ester (L-NAME, 10<sup>-5</sup> M), and the cyclooxygenase inhibitor meclofenamate (10<sup>-5</sup> M). Angiotensin II (AII, 10<sup>-6</sup> M) was given prior to the hypoxic challenge, to allow comparison with a constrictor that does not



primarily act via inhibition of O<sub>2</sub> sensitive Kv channels. Cycles of AII-hypoxia-normoxia were repeated 3 times, at which point the magnitude of AII and hypoxic constrictions had plateaued.  $\Delta$ AII (mmHg) and  $\Delta$ HPV were calculated during the third cycle, because the magnitude of constriction reaches a plateau after 3 cycles. Blood gas measurements of the perfusate were performed to ensure hypoxia, normoxia and a physiologic pH. Arterial blood gases in normoxia and hypoxia were pH  $7.33 \pm 0.01$ , PCO<sub>2</sub>  $31 \pm 2.5$ , PO<sub>2</sub>  $134 \pm 3.7$ , and pH  $7.37 \pm 0.02$ , PCO<sub>2</sub>  $31 \pm 1.6$ , PO<sub>2</sub>  $42 \pm 2.1$ , respectively. There was no significant difference in pH and PCO<sub>2</sub>.

#### Immunoblotting

[0075] Immunoblots were performed and analyzed as previously described in Michelakis ED, et al. (2002) *Circulation* 105:244-50, using Kv1.5 and Kv2.1 channel (Alomone, Jerusalem, Israel) and GFP antibodies (200 $\mu$ L diluted 1:1000, Clontech Laboratories, Palo Alto, CA) on homogenized lungs. Signal intensity of the immunoreactive Kv bands were normalized to the expression of  $\alpha$ -SM actin. The commercially available antibody for Kv1.5 demonstrated cross-reactivity between rat and human Kv1.5, as illustrated in Figure 3C.

#### Real-Time Polymerase Chain Reaction

[0076] To specifically assess the exogenous human Kv1.5 we used quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR). The primers were designed to be selective for human Kv1.5 and did not detect rodent Kv1.5. Total RNA was extracted using RNEasy Mini Kit (Qiagen, Mississauga, Canada) for a total of 25  $\mu$ g quantified with UV spectrophotometry. GAPDH was used as a housekeeping gene. The reaction used 25 ng of RNA in 25  $\mu$ L volume using Kv1.5 primer (500nM), and a TaqMan probe that we designed (200nM). Reverse transcription proceeded for 30 min at 48°C, denaturing for 10 min at 95°C, and annealing at 95°C for 15 sec. Extension occurred for 1 minute at 60°C over 40 cycles in ABM PRISM 7700 Sequence Detector System (Applied Biosystems, Foster City, California). Copy number was expressed relative to GAPDH, using the N-S group as a calibrator. mRNA, was expressed as  $2^{-Ct}$  (Ct is cycle time), a measure reflecting the quantitative expression of the Kv mRNA relative to the reporter, glyceraldehyde phosphate dehydrogenase, GAPDH.

## Immunohistochemistry

[0077] Immunohistochemistry for Kv1.5 was performed on paraffin-embedded, formaldehyde-fixed lungs counterstained with hematoxylin, as previously described in Reeve HL, et al. Alterations in a redox oxygen sensing mechanism in chronic hypoxia. *J Appl Physiol.* 2001;90:2249-56. Competition assays have previously shown the specificity of the antibody as discussed in Michelakis ED, et al. (2001) *Am. J. Physiol. Lung Cell Mol Physiol.* 280:L1138-47 and the controls lacking primary antibody showed no staining.

## Confocal Microscopy

[0078] Fluorescent confocal images were obtained with a Zeiss Axiovert 100M inverted microscope. Green fluorescence was measured, using an LSM-510 confocal microscope (Zeiss, Toronto, Canada), at the following wavelengths (excitation 488nm, detection 505-530nm).

## Electrophysiology

[0079] Fresh PASMC's were isolated from fourth division PA's by enzymatic dispersion and studied using conventional whole-cell patch-clamp technique at room temperature, as previously described in Archer SL, et al. (1998) *J. Clin. Invest.* 101:2319-30, and Michelakis ED, et al. (2001) *Am. J. Physiol. Lung Cell Mol. Physiol.* 280:L1138-47. All cells were voltage-clamped at a holding potential of  $-70$  mV. Currents were evoked in stepwise fashion from  $-70$  mV to  $+70$  mV with test pulses of 200ms. Whole-cell currents were divided by the capacitance of the cell, yielding current density. The pipette solution (intracellular) contained (mmol/L): KCl 134,  $\text{KH}_2\text{PO}_4$  1.2,  $\text{MgCl}_2$  1.0, HEPES 5, pH 7.30,  $\text{Na}_2\text{ATP}$  5 and EGTA 5.

## Drugs and Statistics

[0080] All drugs were obtained from Sigma-Aldrich Chemical Co (St. Louis. MO), unless otherwise stated. Values are expressed as mean  $\pm$  SEM. Intergroup differences were assessed using factorial ANOVA. Post hoc analysis was performed using a Fisher's probable least significant

difference test (Statview 5.0, SAS Institute, Cary, NC). A  $p < 0.05$  was considered statistically significant.

[0081] The following methods and materials relate to Examples 7-12:

#### DA Rings

[0082] DAs excised from 26 neonates with hypoplastic left heart syndrome during the Norwood procedure (age  $9 \pm 2$  days, 12 female, arterial  $PO_2 \sim 40$  mmHg) were used. DAs were transported in iced saline, maintained in hypoxia and used within 1 hour. Ring tension was recorded as previously described in Michelakis E, et al. (2000) Lancet 356:134-7.

[0083] Optimal passive ring tension was determined to be 1 g, as defined by the maximal constriction to 80 mM KCl. Tension was recorded using a force transducer connected to a MacLab A-D convertor (AD Instruments, Toronto, Canada). Tension was recorded from rings bubbled with 95%  $N_2$  and 5%  $CO_2$  in Krebs' solution, to mimic in utero conditions ( $PO_2$  40 mmHg, pH 7.4,  $pCO_2$  40-50 mmHg). Normoxia was created by bubbling with 20%  $O_2$  and 5%  $CO_2$  (balance  $N_2$ ) resulting in  $PO_2$  150 mmHg, pH 7.4, and  $PCO_2$  40 mmHg. Optimal resting tension was previously found to be 1000 mg, as described in Michelakis E, et al. (2000) Lancet 356:134-7. To exclude the contribution of several endothelial-derived vasoactive substances, the Krebs' solution also contained meclofenamate 17  $\mu$ M to inhibit PGHS and L- $N^G$ -nitroarginine-methylester (L-NAME)  $10^{-5}$  M to inhibit NOS.

#### Whole cell patch clamping technique

[0084] Current and voltage clamp technique, SMC isolation and pipette solutions were performed as previously described in Michelakis ED, et al. (2002) Circ Res. 90:1307-15. The response to  $O_2$ , ETC inhibitors and the membrane permeable  $H_2O_2$  analog, t-butyl hydrogen peroxide, were compared between DAsMCs enzymatically dispersed from fresh DAs versus those maintained in tissue culture for 72 hours (either under normoxic or hypoxic conditions).

[0085] Cells were voltage clamped at a holding potential of -70 mV and currents were evoked by 10 mV steps to +50mV using test pulses of 200 ms duration. Data were recorded and analyzed using pCLAMP 6.02 software (Axon Instruments, Foster City, CA). Current density was calculated (pA/pF) and plotted against voltage.

#### DASMC $E_M$

[0086] DASMC  $E_M$  was measured both using patch clamp technique in current clamp mode and noninvasively with DiBAC<sub>4</sub>(3) (20 $\mu$ M, bis-barbituric acid oxonol), a potentiometric dye that increases green fluorescence upon depolarization. DiBAC<sub>4</sub> loaded cells or intact DA rings were stimulated with multi-photon excitation at 740 nm and emission was measured in the green range, 505-530nm. DASMCs were studied after culture in normoxic or hypoxic environment for 4-5 days. The acute change in  $E_M$  that occurred in response to 4-AP (10mM), KCL (80mM) or a switch in PO<sub>2</sub> from 40 to 120mmHg was measured.

#### Laser capture microdissection

[0087] LCM utilizes a microscope platform combined with a low energy infrared laser to melt a plastic capture film onto the flash frozen human ductus arteriosus. The PixCell II LCM System (Arcturus Engineering, Mountain View, CA) is used to selectively remove specific tissue layers from the DA wall. The machine settings were as follows: slice thickness 7 $\mu$ M, power 45mW, duration 1.5ms. The freshly section ductus was mounted without a coverslip on a DNA-free microscope slide. The tissue was dehydrated using the HistoGene LCM Frozen Section Staining Kit and then the dissected section was placed on a thermoplastic membrane pre-mounted on optically transparent caps. After visual confirmation of the adequacy of the dissection by examining the tissue in the cap, the specimen was placed in RNA-later® for subsequent qRT-PCR.

#### Real-time Polymerase Chain Reaction

[0088] Quantitative real-time Polymerase Chain Reaction (qRT-PCR) was used to quantify human Kv channel mRNA, relative to GAPDH. Total RNA was extracted using RNeasy Mini Kit (Qiagen, Mississauga, Canada) and quantified with UV spectrophotometry. Quantitative real-time

polymerase chain reaction (qRT-PCR) was used to quantify human Kv channel mRNA and expression of rat Kv2.1 mRNA transgene. The TaqMan One-Step RT-PCR Master Mix reagent kit was used (Applied Biosystems, Foster City, CA). The reaction used 50ng RNA in 50µl using the relevant primer (500nM), and TaqMan probe (200nM), as designed by us. The assay was performed using an ABI PRISM 7700 Sequence Detector System (Applied Biosystems). Reverse transcription proceeded for 30 min at 48°C. AmpliTaq Gold activation occurred for 10min at 95°C. Subsequently, 40 cycles of PCR were performed. Each cycle consisted of 15 seconds of denaturing (at 95°C) and 1 minute of annealing and extension (at 60°C).  $2^{-Ct}$  is a ratio of the expression of the Kv channel to glyceraldehyde dehydrogenase (GAPDH).

[0089]  $2^{-Ct}$  calculation:  $2^{-Ct}$  is a conversion factor allowing the amount of Kv mRNA to be expressed in terms of copy number relative to the calibrator (the sample with the least amount of Kv mRNA) and normalised to expression of a housekeeping gene, GAPDH.  $Ct$ =threshold cycle for target amplification.

[0090] The  $Ct$  Kv2.1 was computed for each sample (Equation 1). The largest  $Ct$  (indicating the smallest amount of Kv2.1) is defined as the calibrator.

$$\text{Equation (1)} \quad Ct_{Kv2.1} = Ct_{Kv2.1} - Ct_{GAPDH}$$

[0091] Then the relative copy number  $2^{-Ct}$  is calculated for each sample using formula 2

$$\text{Equation (2)} \quad Ct = \text{calibrator} - Ct_{Kv2.1}$$

[0092] In the case of the sample that is experimentally selected as the calibrator (the lowest expressing sample), Equation 2 yields a value of 0 (subtracting the value from itself). By expressing the  $Ct$  as an exponent of 2, the copy number in the calibrator becomes  $2^0=1$ , allowing easy expression of the larger amounts of Kv mRNA in other specimens relative to this value.

#### Measurement of ROS by Chemiluminescence

[0093] The Lucigenin-enhanced chemiluminescence is sensitive for ROS but does not differentiate amongst the redox species. DA rings were loaded with lucigenin 5 µM and placed in a 2

ml heated cuvette at 37°C. Counts were recorded using a Packard 1900CA Liquid Scintillation Analyzer.

#### H<sub>2</sub>O<sub>2</sub> assay

[0094] H<sub>2</sub>O<sub>2</sub>, was measured using a specific, fluorometric AmplexRed® assay, as previously described in Michelakis ED, et al. (2002) Circ Res. 90:1307-15. An independent, specific measure of the candidate redox mediator, H<sub>2</sub>O<sub>2</sub>, was made using the one-step, fluorometric Amplex Red (Molecular Probes, Eugene, OR) assay. The assay detects H<sub>2</sub>O<sub>2</sub> using 10-acetyl-3,7-dihydroxyphenoxazine (Amplex Red reagent) a stable probe that, in the presence of horseradish peroxidase (HRP), reacts with H<sub>2</sub>O<sub>2</sub> with a 1:1 stoichiometry to produce the highly fluorescent substance, resorufin. The assay was calibrated (Figure 15) and found to be linear over the range of 0.25 to 5.0μM. Freshly harvested DA rings were placed in a normoxic or a hypoxic solution containing AmplexRed and, after 20 minutes, fluorescence was recorded (excitation 530nm, emission 590nm), see Figure 15.

#### Mitochondrial membrane potential

[0095] Mitochondrial membrane potential ( $\Delta\Psi_m$ ) was measured using two independent and well-validated probes JC-1 and TMRM (tetramethyl rhodamine methyl ester), as previously described in Michelakis ED, et al. (2002) Circ Res. 90:1307-15.

[0096] First-passage cultured DASC were loaded with either JC-1 (1μM) or TMRM (20nM) for 30 minutes (37°C) at 37 C. Confocal images were obtained within 30 minutes using a Zeiss Axiovert 100M inverted microscope equipped with an Apochromat 40x1.2 water-corrected objective. Settings (amplifier gain, pin hole size and filter set) were kept constant between experiments.

[0097] JC-1, a cationic fluorescent dye that exhibits potential-dependent mitochondrial accumulation is used extensively to study  $\Delta\Psi_m$ . JC-1 fluoresces in the red spectra in hyperpolarized mitochondria (high  $\Delta\Psi_m$ ) and in the green spectra in depolarized mitochondria (low  $\Delta\Psi_m$ ). KCl (40mM) was used to clamp the plasmalemmal membrane potential in some experiments. This did

not alter JC-1 fluorescence (not shown), confirming the specificity of this potentiometric dye for the  $\Delta\Psi_m$  and not the plasmalemmal  $E_M$ . TMRM binds the inner and outer aspects of the inner mitochondrial membrane and accumulates in the mitochondria at greater quantities than predicted by the Nernst equation. TMRM fluorescence red in proportion to  $\Psi_m$ . A 488nm Argon laser was used for excitation and the resultant red/green fluorescence was quantified in channels 1 and 2 using LP 560nm and BP 505-530nm filters, respectively. 8-bit images were collected with a laser loiter time of 4.48 $\mu$ s/pixel. Pinholes yielded optical slices of 1 $\mu$ m. Results are expressed as the ratio of red/green channel fluorescence.

#### Ex-vivo gene transfer

[0098] Adenoviruses (serotype 5, Ad5) carrying genes for rat Kv2.1 and green fluorescent protein (GFP) (GFP, Ad5-GFP-Kv2.1) or GFP alone (Ad5-GFP), each under a CMV promoter, were constructed using the Adeasy-1 system as previously described in Michelakis ED, et al. (2002) *Circulation* 105:244-50.

[0099] Adenoviruses (serotype 5) were constructed using the Adeasy-1 system as previously described in He TC, et al., (1998) *Proc. Natl. Acad. Sci. U.S.A.* 95:2509-14; and Michelakis, ED et al., (2002) *Circulation* 105:244-50. A recombinant adenovirus encoding GFP and Kv2.1 was prepared using Adeasy-1, an adenoviral backbone vector, which contains adenovirus (serotype 5) genomic DNA with E1 and E3 deleted. A 2609 bp cDNA fragment encoding the open reading frame of the rat Kv2.1 channel was excised from its original pBK-CMV plasmid (kindly provided by Dr. K Takimoto, University of Pittsburgh) using restriction endonucleases Not I and Sal I and ligated into the Not I and Sal I sites of pAdTrack-CMV, which contains a kanamycin resistance gene and two cytomegalovirus (CMV) promoters (one promoter located upstream of GFP and the other upstream of Kv2.1). When pAdTrack-CMV and Adeasy-1 are co-transformed into BJ5183 cells, the Kv2.1 gene undergoes homologous recombination with the adenoviral backbone resulting in a plasmid that contains the Kv2.1 and GFP genes. The resultant pAdTrack-CMV Kv2.1 construct was linearised with a Pme I restriction endonuclease digest, transformed together with supercoiled adenoviral vector Adeasy-1 into BJ5183 cells and plated on LB plates containing kanamycin. Subsequent colonies were isolated and the plasmid DNA was purified using plasmid purifying columns

(Qiagen). The plasmid containing Kv2.1 cDNA within the adenoviral DNA was selected, amplified, purified, linearised and transfected into HEK 293 cells using LipofectAMINE reagent. Five days after transfection, plates that demonstrated complete cell lysis were collected and analyzed for Kv2.1 cDNA using PCR. Upon confirmation of the Kv2.1 cDNA in the viral genome, multiple rounds of Ad5Kv2.1 replication were performed in HEK 293 cells. The resulting virus carrying GFP and Kv2.1 cDNA was isolated, precipitated and concentrated by discontinuous CsCl gradient. The final viral titer obtained for Ad5-GFP-Kv2.1 was  $1.5 \times 10^9$  pfu/ml. 24 hours incubation with recombinant replication deficient adenovirus (Ad5-GFP-Kv2.1) achieved 90% infection rates in Chinese hamster ovary cells (CHO) grown and kept under hypoxia.

[0100] Vectors carried the genes for rat Kv2.1 and green fluorescent protein (GFP) or GFP alone, each under a CMV promoter. Twelve hours incubation with recombinant replication deficient adenovirus (Ad5-GFP-Kv2.1) transduced 90% of Chinese hamster ovary cells and generated a functional Kv2.1 current. DA were incubated for 12 hours with either vehicle (normal saline), Ad5-GFP or Ad5-GFP-Kv2.1, the virus was then washed off and the vessels were kept in either a normoxic ( $PO_2 \sim 120$  mmHg) or hypoxic ( $PO_2 \sim 45$  mmHg) incubator for 60 hours (total incubation 72 hours). Successfully infected vessels were selected based on their green fluorescence (excitation 488nm, detection 505-530nm). The finding that GFP fluorescence is at a much lower intensity than DiBAC<sub>4</sub> fluorescence allowed measurement of  $E_M$  in infected rings by increasing the threshold for detection of green emission.

#### Statistics and drugs

[0101] Values were expressed as the mean $\pm$ SEM. Intergroup differences were assessed by Student's paired t-test or an ANOVA (factorial or repeated measures) as appropriate. Post hoc analysis used a Fisher's probable least significant difference test (Statview 4.02, Abacus Concepts). A  $P < 0.05$  was considered statistically significant. Regression analysis was also performed using Statview.

[0102] All drugs were dissolved in saline and were obtained from Sigma-Aldrich (St. Louis, MO) unless otherwise stated. Antibodies to ETC complexes were purchased from Molecular Probes



(Eugene, OR). The antibodies were directed against NADH ubiquinol oxidoreductases (Complex I, alpha complex, ~39 kDa), succinate-ubiquinol oxidoreductase (Complex II flavoprotein, ~70 kDa), ubiquinol-cytochrome c oxidoreductase (Core 2 subunit, Complex III ~45kDa) and cytochrome c oxidase (COX chain I, ~40kDa). Kv channel antibodies were from Alomone (Jerusalem, Israel, respectively. MnSOD antibody was from Upstate Biotech (New York, Lake Placid, New York).

#### Example 1

##### Hemodynamics

[0103] CH increased mean PAP in all hypoxic groups compared to N-S ( $p < 0.01$ , see Figure 1). There was no significant difference in mean PAP amongst the CH groups. CI was significantly greater in the CH-Ad5-Kv1.5 group compared to CH-S and CH-Ad5-GFP ( $p < 0.05$ , Figure 1). PVRI was increased in the CH-Ad5-GFP and CH-S groups but was restored to normoxic levels in the CH-Ad5-Kv1.5 group ( $p < 0.05$ , Figure 1). The RV / LV + septum ratio, an indicator of RVH, was significantly higher in all CH groups compared to N-S ( $p < 0.001$ , Figure 1). The SBP for the N-S, CH-S, CH-Ad5-GFP and CH-Ad5-Kv1.5 groups was (mmHg  $\pm$  SEM)  $100 \pm 8$ ,  $94 \pm 11$ ,  $90 \pm 8$ , and  $100 \pm 5$  ( $p = \text{NS}$ ). The SVRI for the N-S, CH-S, CH-Ad5-GFP and CH-Ad5-Kv1.5 groups was (in mmHg/mL/min)  $0.34 \pm 0.05$ ,  $0.63 \pm 0.13$ ,  $0.83 \pm 0.35$ ,  $0.25 \pm 0.06$  ( $p = 0.15$ ).

#### Example 2

##### Isolated Perfused Lungs

[0104] HPV was reduced in the CH-Ad5-GFP and CH-S compared to N-S group. HPV was restored to normal levels in the CH-Ad5-Kv1.5 group ( $p < 0.05$ , see Figure 2), but not in the group receiving the control virus (CH-Ad5-GFP). The A-II response was not significantly different amongst groups, illustrated in Figure 2B, \* $p < 0.05$  vs. N-S; †  $p < 0.05$  vs CH-S.

#### Example 3

##### Confocal Microscopy

[0105] Figure 3A-C illustrate a demonstration of effective gene transfer to the distal airways and PA. Confocal microscopy revealed GFP fluorescence in CH-Ad5-Kv1.5 and CH-Ad5-GFP groups. GFP was found in airways, small, resistance pulmonary arteries and veins shown in Figure 3A. There was no GFP fluorescence in the CH-S group, as shown in Figure 3A.

#### Example 4

##### Kv1.5 and GFP expression

[0106] Immunoblotting for GFP, shown in Figure 3B and Kv1.5, shown in Figure 3C, revealed markedly increased expression of both proteins in the CH-Ad5-Kv1.5 group. In the lower part of panel C the mean data are shown on a logarithmic scale, normalized to smooth muscle  $\alpha$ -actin was used as a control for total protein loading, (\*  $p < 0.05$  differs from N-S). As expected, there was no GFP expression in the N-S or CH-S lungs. Kv1.5 protein expression (expressed as a % of the  $\alpha$ -SM actin signal) was reduced in CH-S versus N-S, as shown in Figure 3C. qRT-PCR, performed on individual, isolated resistance PA, demonstrated that endogenous rat Kv1.5 mRNA expression decreased significantly in response to CH, as shown in Figure 4B. The loss of Kv1.5 was not nonspecific; expression of several other channels was not depressed (Kir2.1 and the large conductance calcium-sensitive  $K^+$  channel,  $BK_{Ca}$ ), as shown in Figure 4B. Utilizing a specific primer for exogenous human Kv1.5 in qRT-PCR, human Kv1.5 mRNA was exclusively found in the Ad5-Kv1.5 treated lungs, as shown in Figure 4C. This group also experienced a 3-log order increase in net Kv1.5 protein expression, as shown in Figure 3C. Interestingly, overexpression of Kv1.5 was not associated with altered expression of another 4-AP sensitive Kv channel, Kv2.1, as shown in Figure 3C.

#### Example 5

##### Immunohistochemistry

[0107] There was minimal Kv1.5 staining in the small PAs of the CH-S group, as shown in Figure 4A. Using identical technique, Kv1.5 staining was prominent in the pulmonary arteries, veins and airways of the CH-Ad5-Kv1.5 group, as shown in Figure 4A. Immunohistochemistry for Kv1.5

(brown signal) in both airway and PAs is increased in the CH-Ad5-Kv1.5 group compared to the CH-S group. qRT-PCR demonstrates that endogenous rat Kv1.5 mRNA expression decreased significantly in response to CH. It is important to note the comparison of relative copy number is only valid within a group (i.e. one cannot compare the absolute expression of Kv1.5, BK<sub>Ca</sub>, Kir channel) expression. qRT-PCR shows that human Kv1.5 mRNA is only present in isolated PAs from CH-Ad5-Kv1.5 lungs.

#### Example 6

##### Electrophysiology

[0108] Hypoxia and 4-AP caused a similar, reversible inhibition of  $I_K$  in N-S PSMCs. In CH-S PSMCs, current density was significantly decreased and sensitivity to both 4-AP and hypoxia was lost, as shown in Figure 6. CH-Ad5-Kv1.5 treatment increased the magnitude of the normoxic current density, as shown in Figure 5 and restored the hypoxia and 4-AP sensitivity of the current, as shown in Figure 6. There was no effect of the Ad5-GFP on the electrophysiological effects of CH, as shown in Figures 5 and 6. Gene transfer resulted in current densities that were more than double those in the noninfected normoxic PSMCs, as shown in Figure 5. Furthermore, the increase in current density occurred across the range of voltages from -50 to +70 mV.

[0109] The following examples relate to the assessment of O<sub>2</sub> constriction of the human DA via inhibition of DASMCM Kv channels.

#### Example 7

##### Kv channels control tone

[0110] Fresh human DA rings were studied in hypoxia to mimic conditions in utero, except when otherwise specified. The Kv channel inhibitor 4-AP (1-10mM) significantly constricts the human DA in a dose-dependent manner as shown in Figure 1A; iberiotoxin (IBTx, 200 nM, a BK<sub>Ca</sub> blocker) does not. The magnitude of O<sub>2</sub> and 4-AP constriction are strongly correlated as shown in Figure 7B. Although both 4-AP and IBTx significantly inhibit whole cell K<sup>+</sup> current ( $I_K$ ) as shown in

Figure 7C and D, IBTx causes minimal inhibition of  $I_K$  at potentials close to the resting  $E_M$  as shown in Figure 7E. In contrast,  $O_2$  and 4-AP cause similar, significant decreases in  $I_K$  at  $-30mV$ , as shown in Figure 7E.

[0111] mRNA for Kv1.5 and Kv2.1 is expressed in the media and SMCs of DA; selectively extracted with Laser Capture Microdissection (LCM), as shown in Figure 8A. Using LCM, a circumferential ring of media was selectively removed from a human DA. The presence of Kv2.1 and Kv1.5  $\alpha$ -subunit proteins and SM  $\alpha$ -actin was confirmed by performing qRT-PCR on the isolated ring of media. The expression of Kv1.5 in the DASMCMC is further confirmed by immunocolocalization (B) in which the SMCs in the media of an intact human DA are stained for  $\alpha$ -SM actin (green staining) and Kv1.5 (red). The colocalization results in the combined image showing yellow SMCs. Nuclei are stained with Hoechst 33342. Note the SMCs are separated by a significant amount of unstained myxoid tissue.

[0112] This technique is important because the DA is composed of many cell types and LCM allows specific selection of the media and thus preferential measurement of channel expression in SMCs. Furthermore, immunofluorescent co-localization, shows that Kv2.1, as shown in Figure 8B and Kv1.5 protein is expressed in SM  $\alpha$ -actin positive DASMCMC. This is also confirmed by conventional immunohistochemistry shown in Figure 16.

#### Example 8

The Proximal ETC is the  $O_2$  Sensor.

[0113] Both rotenone, a complex I ETC inhibitor, and antimycin, a complex III inhibitor, relax the  $O_2$ -precontracted DA, mimicking hypoxia, as shown in Figure 9A-B. In contrast, cyanide does not dilate the DA. Whereas either rotenone or antimycin alone only partially relax the normoxic DA, pretreatment with both inhibitors completely eliminates  $O_2$  constriction, as shown in Figure 9A, (\*  $P < 0.05$ ). ETC inhibitor relaxation is not due to DA damage or nonspecific suppression of tone, since phenylephrine constriction is unaltered by rotenone and antimycin A, as shown in Figure 9A. Further support for the contention that  $O_2$  and rotenone target the same mechanism is the strong, direct

correlation between the magnitude of O<sub>2</sub>-constriction and rotenone-relaxation, as shown in Figure 9C, R<sup>2</sup>=0.74.

[0114] In fresh human DASMCM, O<sub>2</sub> rapidly and reversibly inhibits I<sub>K</sub> as shown in Figures 9D-F. Rotenone mimics hypoxia, precisely restoring the current that was acutely suppressed by O<sub>2</sub>. In contrast, cyanide (a complex IV blocker, 10μM) does not alter I<sub>K</sub>, data not shown. I<sub>K</sub> is reversibly inhibited by normoxia within 5 minutes, (\*, \*\* P<0.05 values differ from hypoxia and normoxia, respectively).

[0115] These data provide strong evidence that the mechanism by which both proximal ETC inhibitors and hypoxia relax the DA is DASMCM Kv activation.

#### Example 9

A new model of ionic remodeling: DAs in tissue culture.

[0116] The effects of O<sub>2</sub> and rotenone on tone, as shown in Figure 10A, K<sup>+</sup> channel function as shown in Figure 10B and 11A-C, and expression as shown in Figure 11E, were studied in DAs kept in normoxic versus hypoxic tissue culture for 72 hours. The chronically normoxic DA rings retain the ability to constrict to phenylephrine, whereas they lose both the O<sub>2</sub>-constriction and the rotenone-relaxation responses, as shown in Figure 10A. In fresh DA ETC blockers inhibit O<sub>2</sub> constriction (gray bars), without altering the response to phenylephrine (PE, white bars). Chronic exposure of DA rings to O<sub>2</sub>, followed by study of ring tension in a hypoxic tissue bath (cross hatched bars) shows that the constrictor response to O<sub>2</sub> (but not PE) is lost and rotenone no longer causes relaxation. SMCs from chronically normoxic DAs have a significantly decreased current density, compared to the freshly isolated cells studied under identical conditions, as shown in Figure 10B. In addition, when these DASMCM are returned to hypoxic conditions, their I<sub>K</sub> is unresponsive to acute normoxia, 4-AP or rotenone, as shown in Figure 10B. DASMCM dispersed from DAs cultured in chronic normoxia and then studied under hypoxic conditions, have decreased current density. These ionically remodeled cells have lost their responsiveness to both O<sub>2</sub> and rotenone. Representative raw traces are shown to the right of the mean data. The loss of O<sub>2</sub> and ETC sensitivity in chronically normoxic DA is associated with basal, hypoxic E<sub>M</sub> depolarization and loss of the ability to acutely

depolarize in response to either O<sub>2</sub> or 4-AP, whereas the response to KCl is preserved, as shown in Figure 11A-D. Confocal microscopy of intact DA rings reveals depolarization (more green) in the half of the ring exposed to O<sub>2</sub> for 72 hours than in the half incubated in hypoxia. The blue stain (Hoechst 33342) marks the nuclei. E<sub>M</sub> measured in green fluorescent units (GFU, the more depolarized the more green) is more depolarized in chronically normoxic DASMCs compared to chronic hypoxic controls, (\* P<0.05). Even when returned acutely to hypoxic conditions, ionically remodeled DASMCs lose their ability to depolarize to 4-AP or O<sub>2</sub> (\* P<0.05 ) but not KCL 80mM.

[0117] The concordant findings of impaired membrane responses to O<sub>2</sub> using both whole-cell current clamp and potentiometric dyes in both DASMC and DA rings excludes the theoretical possibility that this could be an artifact, related to enzymatic dispersion of cells or loss of cell-cell connection.

#### Example 10

Ionic remodeling results from downregulation of O<sub>2</sub>-sensitive Kv channels.

[0118] DAs were divided in thirds and both the function and expression of K<sup>+</sup> channels and ETC complexes were compared in fresh hypoxic DAs, versus DAs cultured in chronic normoxia or chronic hypoxia. In chronic normoxia, mRNA for Kv1.5 and Kv2.1 (measured using qRT-PCR) and Kv4.3, Kv9.3 and BK<sub>Ca</sub> (measured using conventional RT-PCR, as shown in Figure 17 where F=Fresh, H= chronic hypoxic culture 96 hours, N=chronic hypoxic culture 96 hours) is downregulated, relative to the housekeeping gene GAPDH, n=5, \*p<0.05), as shown in Figure 11E. There is a statistically insignificant decrease in Kv expression caused by tissue culture in hypoxia.

[0119] There is no decrease in Kv1.1, Kir2.1, or TASK expression, measured using conventional RT-PCR, suggesting that the downregulation of these O<sub>2</sub>-sensitive channels is somewhat specific, as shown in Figure 17. Although there was also a trend to lower Kv1.5 and Kv2.1 mRNA in chronic normoxia vs. chronic hypoxia, as shown in Figure 5E, this was not statistically significant. Expression of selected subunits from ETC complexes I-IV is unaltered by chronic normoxia, as shown in Figure 18.

## Example 11

### Kv2.1 gene restoration in the ionically remodeled DA.

[0120] If the depressed Kv expression in this model is both real and important, it would follow that restoring Kv expression would be sufficient to restore the missing O<sub>2</sub> responsiveness of chronically normoxic DASCs. Indeed Kv2.1 gene therapy does partially restore O<sub>2</sub> responsiveness, as shown in Figure 12. DAs were divided into 4 pieces. One piece was studied acutely under hypoxia whereas the others were exposed to normoxia for 12 hours in the presence of vehicle, Ad5-GFP or Ad5-GFP-Kv2.1. This was followed by 60 hours of normoxic incubation to allow gene and protein expression. Of the six human DAs infected, successful gene transfer, as measured by GFP fluorescence, was confirmed in four, as shown in Figure 12A-B. The Kv2.1 transgene was derived from rat and, using the species specificity of the qRT-PCR probe, we were able to show that expression of rat Kv2.1 mRNA occurred exclusively in Ad5-GFP-Kv2.1-infected DAs, as shown in Figure 12C, (n=4).† P<0.01. The transgene yielded functional channels, indicated by the fact that DASC isolated from Ad5-GFP-Kv2.1 rings had a larger Kv current compared to the DASC from the noninfected DA, as shown in Figure 12B. Kv2.1 gene transfer, significantly restores the ability of the normoxic DA to respond to O<sub>2</sub> and 4-AP, as shown in Figure 12D and E. In panel D the constrictor responses to O<sub>2</sub> and 4-AP are expressed as a % of the maximal phenylephrine constriction noted in the same rings. Note that infection with a virus containing only GFP is without effect (n=4).

## Example 12

[0121] Mitochondria-derived ROS are the redox mediators of normoxic DA constriction. Inhibitors of the proximal ETC and authentic hypoxia rapidly depolarize  $\Psi_m$  in DASCs in primary, hypoxic culture, as shown in Figure 13A-D. On the left the DASM mitochondria, shown in Figures 13A and B, are imaged with TMRM (nuclei stained with Hoechst 33342) and on the right they are with JC-1 (which shows high  $\Psi_m$  in red and depolarized mitochondria in green). Conversely, cyanide 10 $\mu$ M does not acutely alter  $\Psi_m$ , as shown in Figure 13C. Cyanide also depolarizes  $\Psi_m$ , but only at high doses. P<0.05 value differs from control. Rapid increases in PO<sub>2</sub>

(from 45 to 100 mmHg) hyperpolarize  $\Psi_m$  (increase in the red/green ratio measured using JC-1). Rotenone (10 $\mu$ M) depolarizes this normoxia  $\Psi_m$  (\* P<0.05 value differs from control).

[0122] To address the concern that cyanide should (at some dose) be effective in collapsing  $\Psi_m$ , its effects on a cardiac HL-1 cell line was also assessed. These experiments showed that 10 $\mu$ M CN readily depolarizes  $\Psi_m$  in HL-1 cells, suggesting diversity in mitochondria between vascular vs. cardiac cells, as shown in Figure 19. Thus  $\Psi_m$  in DASMCs is much more sensitive to rotenone than to cyanide, consistent with its lack of electrophysiological and hemodynamic effects.

[0123] Lucigenin-enhanced chemiluminescence (n=2) and H<sub>2</sub>O<sub>2</sub> production (n=5) are increased within minutes by raising PO<sub>2</sub> from 40 to 100 mmHg in freshly isolated, human DA rings, as shown in Figure 14A-B. Rotenone decreases H<sub>2</sub>O<sub>2</sub> production (Figure 14A-B). t-butyl-H<sub>2</sub>O<sub>2</sub> mimics the effects of O<sub>2</sub> on DASMC electrophysiology. It inhibits I<sub>K</sub>, depolarizes fresh hypoxic DASMCs and both these effect are lost after exposure to chronic normoxia, as shown in Figure 14C-D. Figure 14C shows the voltage clamp data illustrating that t-butyl-H<sub>2</sub>O<sub>2</sub> inhibits I<sub>K</sub> in freshly dispersed DASMCs. Figure 14D shows the current clamp data illustrating that t-butyl-H<sub>2</sub>O<sub>2</sub> depolarizes fresh hypoxic DASMCs. This response is preserved in chronically hypoxic DASMCs but is lost in chronically normoxic DASMCs, consistent with their loss of O<sub>2</sub> sensitive Kv channels, (\* P<0.05 value differs from control, † P<0.05 from fresh).

[0124] The following example relates to a further embodiment of the invention using a replication deficient adenovirus containing a site-specific SM-22 promoter.

#### Example 13

[0125] A replication deficient adenovirus containing Kv1.5 cDNA driven by site-specific promoter (smooth muscle 22-alpha; SM22a) was created. A polymerase chain reaction (PCR) was performed on cDNA templates (synthesized by reverse transcriptase-PCR from mRNA of a cardiac transplant pulmonary artery donor, in one case, and the ductus arteriosus of a patient with a single ventricle undergoing correction, in another case) using sense and anti-sense oligonucleotides corresponding to the first and last 20-25 bp of the coding region of Kv1.5 respectively. In addition,



the anti-sense oligonucleotides ended just 5' of the stop codon and had the cDNA sequence encoding the 9 amino acid of c-myc insert. Kv1.5myc cDNA was subcloned into the plasmid CR 2.1-TOPO of TA Cloning kit for subsequent propagation. The resulting cDNA from the plasmid was digested with restriction endonuclease EcoRI and was subsequently ligated in a pBluescript plasmid already containing SM22a promoter (a generous gift from Dr. Bloch). The construct carrying SM22a promoter with Kv1.5myc cDNA was removed via restriction digests, purified and ligated into the pShuttle vector. The pShuttle vector contained adenoviral sequence that allows homologous recombination with Adeasy-1. The resultant pShuttle-SM22a-Kv1.5myc construct was linearized with a PmeI restriction endonuclease digest, transformed together with an adenoviral plasmid (pAdeasy-1) into bacterial BJ5183 cells and plated on LB agar containing kanamycin. The selected colonies containing SM22a and Kv1.5myc were isolated, amplified, purified and linearized (PacI endonuclease digest) and transfected into HEK 293 cells with liposome transfection (LipofectAmine reagent). Plates with complete cell lysis were collected and analyzed for Kv1.5 expression using PCR and immunoblotting using anti-Kv1.5 antibody. The Kv1.5myc positive virus was amplified and isolated. The virus was purified by step-wise discontinuous CsCl gradient and the adenovirus was titrated, as previously performed in creating the Ad5-Kv1.5 and Kv2.1 viruses using a CMV promoter as described above.

[0126] While the embodiment discussed herein is directed to a particular implementation of the invention, it will be apparent that variations and modifications may be effected thereto, by those of skill in the art, without departing from the scope of the invention.